ELISA Kit Accurately Detects Bioactive Hepcidin Levels
By LabMedica International staff writers Posted on 17 Aug 2015 |
Image: The DRG Hepcidin 25 HS enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of DRG International).
An enzyme-linked immunosorbent assay (ELISA) kit has been introduced that accurately detects bioactive hepcidin levels as an additional marker to aid in identifying a variety of disorders.
Hepcidin has been identified as a factor in regulating the amount of iron in humans and unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.
The new Hepcidin 25 (bioactive) HS ELISA kit has an analytical sensitivity of 0.153 ng/mL, with a measuring range of 0 81 ng/mL to 153 ng/mL. Serum or plasma samples can be assessed and the total incubation time is less than two hours. The ELISA is user-friendly as no shaker and no assay buffer is required, and all reagents except wash solution are ready-to-use.
The new DRG Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit is manufactured by DRG International (Springfield Township, NJ, USA) and is more sensitive that their previous product for measuring hepcidin. The DRG Hepcidin 25 (bioactive) HS ELISA Kit is available worldwide, providing a simple, fast and accurate method to test hepcidin levels. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The ELISA kit is Conformité Européenne (CE) marked.
Cyril E. Geacintov, PhD, founder, president and CEO of DRG International, said, “We at DRG International saw the need for an accurate and easy to use hepcidin testing kit and are encouraged by the great success that our customers have seen using the product. This kit is an important step to meet the rapidly growing worldwide interest in hepcidin testing and the applications of that testing in the health and wellness community.”
The new Hepcidin ELISA kit was showcased at the American Association for Clinical Chemistry (AACC) annual meeting held from July 27-30, 2015, in Atlanta (Georgia, USA).
Related Links:
DRG International
Hepcidin has been identified as a factor in regulating the amount of iron in humans and unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.
The new Hepcidin 25 (bioactive) HS ELISA kit has an analytical sensitivity of 0.153 ng/mL, with a measuring range of 0 81 ng/mL to 153 ng/mL. Serum or plasma samples can be assessed and the total incubation time is less than two hours. The ELISA is user-friendly as no shaker and no assay buffer is required, and all reagents except wash solution are ready-to-use.
The new DRG Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit is manufactured by DRG International (Springfield Township, NJ, USA) and is more sensitive that their previous product for measuring hepcidin. The DRG Hepcidin 25 (bioactive) HS ELISA Kit is available worldwide, providing a simple, fast and accurate method to test hepcidin levels. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The ELISA kit is Conformité Européenne (CE) marked.
Cyril E. Geacintov, PhD, founder, president and CEO of DRG International, said, “We at DRG International saw the need for an accurate and easy to use hepcidin testing kit and are encouraged by the great success that our customers have seen using the product. This kit is an important step to meet the rapidly growing worldwide interest in hepcidin testing and the applications of that testing in the health and wellness community.”
The new Hepcidin ELISA kit was showcased at the American Association for Clinical Chemistry (AACC) annual meeting held from July 27-30, 2015, in Atlanta (Georgia, USA).
Related Links:
DRG International
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form